Shares in the company dived after a new anti-obesity treatment missed expectations in a study, denting its chances of ...

Novo Nordisk A/S’s shares fell by the most on record after patients using its experimental obesity shot CagriSema lost less ...

Novo Nordisk stock fell sharply early Friday after the pharmaceutical giant, known for its blockbuster drugs Ozempic and ...

Shares in Ozempic maker Novo Nordisk crashed, after an experimental anti-obesity shot fell short of expectations. The shares ...

A phase 3 trial of Novo Nordisk’s next-generation obesity prospect CagriSema has failed to achieve the level of weight loss ...

Novo shares lost nearly a quarter of their value after an experimental combination treatment called cagrisema fell short of ...

Investors appeared disappointed by CagriSema’s Phase III readout, which showed weight loss that fell short of Novo Nordisk’s ...

Novo Nordisk plans a new trial for its experimental drug, CagriSema, in 2025 after recent trials failed to meet weight-loss expectations. Despite aiding patients to reduce weight by 22.7%, it fell ...

Novo Nordisk announced a new trial for its CagriSema drug after disappointing results in a late-stage trial. The experimental drug, aimed at weight loss, showed less efficiency than expected, leading ...

Investing.com -- Shares of Novo Nordisk (NYSE: NVO) A/S, the Danish pharmaceutical company, experienced a significant drop ...

The pharmaceutical company will establish a production facility in Odense to accommodate multiple product types within the ...

The maker of weight-loss and diabetes drugs has supercharged the Danish economy — but other businesses complain that’s left ...